Ocular Therapeutix Inc (OCUL)
6.18
-0.09
(-1.44%)
USD |
NASDAQ |
May 17, 16:00
6.18
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix Revenue (Quarterly): 14.77M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 14.77M |
| December 31, 2023 | 14.80M |
| September 30, 2023 | 15.08M |
| June 30, 2023 | 15.19M |
| March 31, 2023 | 13.37M |
| December 31, 2022 | 14.08M |
| September 30, 2022 | 11.96M |
| June 30, 2022 | 12.27M |
| March 31, 2022 | 13.19M |
| December 31, 2021 | 12.31M |
| September 30, 2021 | 12.15M |
| June 30, 2021 | 11.72M |
| March 31, 2021 | 7.342M |
| December 31, 2020 | 7.349M |
| September 30, 2020 | 5.876M |
| June 30, 2020 | 1.569M |
| March 31, 2020 | 2.609M |
| December 31, 2019 | 2.256M |
| September 30, 2019 | 0.829M |
| June 30, 2019 | 0.65M |
| March 31, 2019 | 0.492M |
| Date | Value |
|---|---|
| December 31, 2018 | 0.504M |
| September 30, 2018 | 0.498M |
| June 30, 2018 | 0.648M |
| March 31, 2018 | 0.34M |
| December 31, 2017 | 0.487M |
| September 30, 2017 | 0.523M |
| June 30, 2017 | 0.438M |
| March 31, 2017 | 0.475M |
| December 31, 2016 | 0.511M |
| September 30, 2016 | 0.477M |
| June 30, 2016 | 0.441M |
| March 31, 2016 | 0.458M |
| December 31, 2015 | 0.436M |
| September 30, 2015 | 0.429M |
| June 30, 2015 | 0.459M |
| March 31, 2015 | 0.426M |
| December 31, 2014 | 0.505M |
| September 30, 2014 | 0.143M |
| June 30, 2014 | 0.097M |
| March 31, 2014 | 0.027M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.65M
Minimum
Jun 2019
15.19M
Maximum
Jun 2023
9.468M
Average
12.06M
Median
Revenue (Quarterly) Benchmarks
| Amgen Inc | 7.447B |
| Assertio Holdings Inc | 32.45M |
| CytomX Therapeutics Inc | 41.46M |
| EyePoint Pharmaceuticals Inc | 11.68M |
| Cormedix Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -64.85M |
| Total Expenses (Quarterly) | 46.39M |
| EPS Diluted (Quarterly) | -0.49 |
| Enterprise Value | 539.23M |
| Gross Profit Margin (Quarterly) | 91.02% |
| Profit Margin (Quarterly) | -438.9% |
| Earnings Yield | -21.88% |
| Normalized Earnings Yield | -20.87 |